Vaistinė Esra - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,639,055 | 8,629,381 | 10,120,472 | 17,045,547 | 23,148,290 | 27,524,070 | 31,218,437 | 40,531,907 |
| Profit before tax | -171,669 | 170,892 | 88,439 | 431,273 | 425,541 | 377,050 | 226,247 | 186,444 |
| Net profit | -171,669 | 163,194 | 83,514 | 368,973 | 360,893 | 318,635 | 190,888 | 157,949 |
| Equity | -132,403 | 30,791 | 114,305 | 433,278 | 794,173 | 962,807 | 853,695 | 841,644 |
| Liabilities | 1,721,931 | 1,861,912 | 2,685,251 | 3,628,700 | 4,157,419 | 4,222,376 | 4,509,918 | 5,445,727 |
| Non-current assets | 192,158 | 189,877 | 226,766 | 217,456 | 344,934 | 554,444 | 561,273 | 549,477 |
| Current assets | 1,397,370 | 1,702,826 | 2,572,539 | 3,844,221 | 4,606,178 | 4,630,143 | 4,800,318 | 5,736,441 |
| Total assets | 1,589,528 | 1,892,703 | 2,799,305 | 4,061,677 | 4,951,112 | 5,184,587 | 5,361,591 | 6,285,918 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 219,647 | 171,728 | 144,883 |
| Social insurance contributions | - | - | - | - | - | 72,615 | 83,897 | 93,235 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +76.2% | +137.1% | +17.3% | +68.4% | +35.8% | +18.9% | +13.4% | +29.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -10.8% | 8.6% | 3.0% | 9.1% | 7.3% | 6.1% | 3.6% | 2.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 530.0% | 73.1% | 85.2% | 45.4% | 33.1% | 22.4% | 18.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -4.7% | 1.9% | 0.8% | 2.2% | 1.6% | 1.2% | 0.6% | 0.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -4.7% | 2.0% | 0.9% | 2.5% | 1.8% | 1.4% | 0.7% | 0.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 60.5 | 23.5 | 8.4 | 5.2 | 4.4 | 5.3 | 6.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 285,416 | 663,799 | 804,278 | 1,893,950 | 2,276,874 | 2,325,984 | 2,601,536 | 3,377,659 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vaistinė Esra - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-05-25 | 2022-05-25 | 278.94 |
Vaistinė Esra - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Esra, UAB (code 152555844) is a Private Limited Liability Company engaged in retail sale of pharmaceutical products. In 2025, the company generated revenue of €40.53M, up 29.8% year on year and 47.3% over two years, showing a strong expansion in sales. Net profit was €157.9K, compared with €190.9K in 2024 and €318.6K in 2023, indicating that profitability has weakened as revenue has grown. The net profit margin in 2025 was 0.4%, after 0.6% in 2024 and 1.2% in 2023. Total assets increased to €6.29M in 2025 from €5.36M in 2024 and €5.18M in 2023. Equity stood at €841.6K, while liabilities reached €5.45M, leaving an equity ratio of 13.4% and a debt-to-equity ratio of 6.47. Asset turnover was 6.45x, supported by revenue per employee of €3.38M and profit per employee of €13.2K. Overall, the company combines rapid turnover growth with thin margins and a leveraged balance sheet.